Treatment Response to Neoadjuvant Therapy in Squamous Esophageal Cancer-Correlation Between Metabolic Response and Histopathology.
Abdeali Saif Arif KaderiJiwnani SabitaVirendra Kumar TiwariAkash PawarDevayani NiyogiPublished in: Journal of gastrointestinal cancer (2024)
Our study confirms the correlation of post neoadjuvant chemotherapy PET SUV with histopathological response, the cut-off of SUV being 5.05 in our cohort. This confirms the predictive value of FDG PET as demonstrated in other studies. Furthermore, its prognostic value with respect to survival has been verified in multiple other studies. With larger scale randomized studies, we may be able to identify the group of patients who have borderline operability anatomically as well as physiologically, where alternative treatment regimens may be indicated to improve outcomes.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- pet ct
- positron emission tomography
- end stage renal disease
- lymph node
- case control
- pet imaging
- computed tomography
- ejection fraction
- rectal cancer
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- squamous cell carcinoma
- sentinel lymph node
- prognostic factors
- type diabetes
- open label
- randomized controlled trial
- radiation therapy
- high grade
- clinical trial
- bone marrow
- metabolic syndrome
- placebo controlled
- adipose tissue
- cell therapy
- phase ii
- study protocol
- replacement therapy